Share

November 01, 2016; 87 (18) Article

Female advantage in verbal memory

Evidence of sex-specific cognitive reserve

Erin E. Sundermann, Pauline M. Maki, Leah H. Rubin, Richard B. Lipton, Susan Landau, Anat Biegon, For the Alzheimer's Disease Neuroimaging Initiative
First published October 5, 2016, DOI: https://doi.org/10.1212/WNL.0000000000003288
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
511

Share

Article Information

vol. 87 no. 18 1916-1924
DOI: 
https://doi.org/10.1212/WNL.0000000000003288
PubMed: 
27708128
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received April 18, 2016
  • Accepted in final form July 14, 2016
  • First Published October 5, 2016.

Article Versions

Copyright & Usage: 
© 2016 American Academy of Neurology

Author Disclosures

    1. Erin E. Sundermann, PhD,
    2. Pauline M. Maki, PhD,
    3. Leah H. Rubin, PhD,
    4. Richard B. Lipton, MD,
    5. Susan Landau, PhD,
    6. Anat Biegon, PhD;
    7. For the Alzheimer's Disease Neuroimaging Initiative
  1. Erin E. Sundermann, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Travel award from the Alzheimer's Association International Conference (AAIC) to present at the AAIC 2015 annual meeting

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Fees for consulting on neurocognitive test administration from the Women's Interagency HIV Study (WIHS)

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. My time from 3/2013 to 7/16 is supported by funding for the Einstein Aging Study: National Institute on Aging Grant AG003949, AG026728, TL1RR000087, T32-GM007288, the Leonard and Sylvia Marx Foundation, and the Czap Foundation.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. The Leonard and Sylvia Marx Foundation and the Czap Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Pauline M. Maki, PhD,
    3. Scientific Advisory Boards:

    1. (1) Pfizer (2) Abbott (3) Noven

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Abbott, consultant honorarium (2) Noven, consultant honorarium (3) North American Menopause Society, travel compensation (4) Creative and Novel Ideas in HIV Research, International AIDS Society and NIH, travel compensation (5) Women's Brain Health Initiative, speaking honorarium and travel compensation (6) Society for Women's Health Research, travel compensation

    Editorial Boards:

    1. Editorial Board Member, Menopause, 2009-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Abbott (2) Noven

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. (1) Member of the Board of Trustees of the North American Menopause Society

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Google

    Research Support, Government Entities:

    1. (1) NIMH 1 R01 MH083782-01A1, Principal Investigator, 2009-2014 (2) NIAID 2U01 AI034993-15, Investigator, 2009- 2018 (3) AI 1 P30AI082151-01, Investigator, 2009-2014 (4) NICHD 1K12HD055892-01, Program Director, 2010-2016 (5) NIMH 1R21 MH099978 01A1, Co-Investigator, 2013-2015 (6) NIDA 5 R01 DA012828-12, Co-Investigator, 2013-2017

    Research Support, Academic Entities:

    1. (1) University of Illinois at Chicago, Chancellor's Discovery Fund, 2013-2015

    Research Support, Foundations and Societies:

    1. (1) International AIDS Society and the NIH Creative and Novel Ideas in HIV Research

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Leah H. Rubin, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIMH: 1K01MH098798-01

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Richard B. Lipton, MD,
    5. Scientific Advisory Boards:

    1. Allergan, e-Neura, Merck

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Serve as consultant, advisory board member or received honoraria from: Alder, Allergan, American Headache Society, Autonomic Technologies, Avanir, Boehringer- Ingelheim, Boston Scientific, Bristol Myers Squibb, CoLucid, Dr. Reddys, Electrocore, Eli Lilly, eNeura Therapeutics, Informa, Merck, Novartis, Pfizer, Teva, Vedanta

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. Wolff's Headache, 8th Edition, Oxford University Press; Informa

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Serve as consultant, advisory board member or received honoraria from: Alder, Allergan, American Headache Society, Amgen, Autonomic Technologies, Avanir, Boehringer-Ingelheim, Boston Scientific, Bristol Myers Squibb, CoLucid, Dr. Reddys, Electrocore, Eli Lilly, eNeura Therapeutics, Merck, Novartis, Pfizer, Teva, Vedanta.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Bristol Myers Squibb Early Detection of Alzheimer's Disease June 2010 - present Vedanta Research Migraine epidemiology and Progression June 2010 - present Boston Scientific Occipital Nerve Stimulation in Migraine March 2013 - present ElectroCore Vagal Nerve Stimulation for Migraine and Cluster May 2013 Novartis Sleep and Migraine September 2012 - present Allergan Botox in Migraine April 2012 - present Allergan Chronic Migraine Epidemiology and Outcome Study January 2012 - present

    Research Support, Government Entities:

    1. P01 AG03949 4/1/11-3/31/16 Einstein Aging Study Role: Principle Investigator 1KL2RR025749 07/01/09-06/30/13 Clinical and Translational Science Award (CTSA) Research Career Development Award Role: Primary Mentor R01AG022374 8/1/10-7/31/15 Biomarkers in Early Alzheimer?s Disease Role: Investigator R01AG034119 8/1/10-7/31/15 Two Preclinical Latent Scores to Predict Occurrence of DAT Role: PI, Einstein Site R01AG012101 9/15/10-7/31/15 MRI Progression Markers of Cognitive Decline in the Elderly Role: PI, Einstein Site 1R01AG039409-01 Stress, Unconstructive Repetitive Thought & Cognitive Aging 4/1/11-3/31/16 Role: PI, Einstein Site 1R01AG038651-01A1 Role of impaired cognitive states & risk factors in conversion to mixed dementias 9/1/11-8/31/16 Role: PI, Einstein Site 1U10NS077308- 01 9/30/11-8/31/18 Einstein Center for Excellence for Clinical Trials in Neuroscience Role: PI NIH 4/1/12-3/31/17 Behavioral Weight Loss as a Treatment for Migraine in Obese Women Role: Investigator NIH 1R01AG042595 - 01A1 Stress, cognition, repetitive unconstructive thoughts and inflammatory markers Role: Investigator

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. S & L Marx Foundation Alzheimer's Research

    Stock/Stock Options/Board of Directors Compensation:

    1. eNeura Pharma

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. Oxford University Press; Baxter Publishing

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Susan Landau, PhD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Janssen/J&J Research & Dev, speaking honoraria and travel fees (2) Mount Sinai Medical Center, travel fees

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Consulting work for Biogen Idec, Synarc

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) National Institutes of Health Grant U01 AG024904 Alzheimer's Disease Neuroimaging Initiative (ADNI) (2) W81XWH-12-2-0012 DOD ADNI

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Anat Biegon, PhD;
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. 1. NIH 1R01CA195506-01 (Cohen&Biegon MPI) 5/19/2015-5/18/2017 2. NIH 1R21CA179425-01 (Cohen and Biegon, co-PIs) 9/19/2014-9/18/2016 3. NIH 1R21DA032858 (MPI: Hildebrandt, Biegon) 2/1/12- 1/31/16

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. For the Alzheimer's Disease Neuroimaging Initiative
  1. From the Einstein Aging Study and the Department of Neurology (E.E.S., R.B.L.), Albert Einstein College of Medicine, Bronx, NY; Department of Psychiatry (P.M.M., L.H.R.), University of Illinois at Chicago; Helen Wills Neuroscience Institute (S.L.), University of California, Berkeley; and Department of Neurology (A.B.), State University of New York, Stony Brook.
  1. Correspondence to Dr. Sundermann: erin.sundermann{at}einstein.yu.edu
View Full Text

Article usage

Article usage: October 2016 to May 2022

AbstractFullPdfSource
Oct 20163188564Highwire
Nov 201618922154Highwire
Dec 201625348Highwire
Jan 201720135Highwire
Feb 201713114Highwire
Mar 201715565Highwire
Apr 20179610Highwire
May 201712943Highwire
Jun 201712921Highwire
Jul 201716012Highwire
Aug 201710331Highwire
Sep 20178023Highwire
Oct 201712430Highwire
Nov 201710911Highwire
Nov 2017172831pmc
Dec 20175201Highwire
Jan 20185921Highwire
Feb 20185642Highwire
Mar 20184912Highwire
Apr 20183921Highwire
Apr 201871414pmc
May 20186401Highwire
Jun 20189302Highwire
Jun 201871010pmc
Jul 20186300Highwire
Aug 20184413Highwire
Aug 201841624pmc
Sep 20184635Highwire
Oct 20188536Highwire
Nov 20187201Highwire
Dec 20183913Highwire
Jan 20194020Highwire
Feb 20193923Highwire
Mar 20195241Highwire
Apr 20194103Highwire
May 20193912Highwire
Jun 20193722Highwire
Jul 20194632Highwire
Aug 20193912Highwire
Sep 20192935Highwire
Oct 201918043Highwire
Nov 20195113Highwire
Dec 20196012Highwire
Jan 20205800Highwire
Feb 20205333Highwire
Mar 20204900Highwire
Apr 20205921Highwire
May 20209600Highwire
Jun 20204211Highwire
Jul 20202000Highwire
Aug 20202000Highwire
Sep 20202700Highwire
Oct 20206524Highwire
Nov 20209122Highwire
Dec 20209431Highwire
Jan 20218901Highwire
Feb 20213411Highwire
Mar 20218420Highwire
Apr 20218511Highwire
May 20216940Highwire
Jun 20218110Highwire
Jul 202110134Highwire
Aug 20215922Highwire
Sep 20215700Highwire
Oct 20216353Highwire
Nov 20219721Highwire
Dec 202110911Highwire
Jan 20224912Highwire
Feb 20227200Highwire
Mar 20226552Highwire
Apr 2022111211Highwire
May 202270285184Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me